756521-08-1

Basic information

• Product Name: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine
• Synonyms: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine;3-[[1-(2,6-Dichloro-3-fluorophenyl)ethyl]oxy]-2-nitropyridine
• CAS NO: 756521-08-1
• Molecular Formula: C₁₃H₉Cl₂FN₂O₃
• Molecular Weight: 331.1265632
• Mol File: 756521-08-1.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine(756521-08-1)
• EPA Substance Registry System: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine(756521-08-1)

Safety Data

• Hazardous Substances Data: 756521-08-1(Hazardous Substances Data)

Usage

General Description

"3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine" is a complex organic compound that falls under the category of aromatic halogenated compound and sub-category of dipyridines. It contains two aromatic rings one is pyridine and the other is phenyl, which are interconnected with ethoxy linkage. It also includes fluoride, chloride, and nitro functional groups that contribute to its unique chemical behaviours. This substance's physical properties, such as its molecular weight, boiling and melting points, or its solubility, have not been fully reported in the scientific literature, implying that it's either relatively new or isn't extensively used in the chemical industry. Nonetheless, due to the presence of halogens, it might have potentially significant reactivity. Its comprehensive toxicity profile and environmental impact are also not well documented.

Upstream product

• 15128-82-2 3-hydroxy-2-nitropyridine 
• 1229457-91-3 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 

Downstream Products

• 877397-71-2 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethyoxyl)-2-aminopyridine 
• 877401-42-8 tert-butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 877400-66-3 (+/-)-PF023401066 
• 877399-08-1 (±)-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 
• 1331786-34-5 (±)-bis(Boc)-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine 
• 1331786-33-4 (±)-bis(Boc)-5-bromo-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)pyridin-2-amine 
• 877399-38-7 5-(1-(azetidin-3-yl)-1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 

Relevant articles and documents

Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants

Despite the initial benefit demonstrated in clinical setting with ALK inhibitors, the challenging resistant mutants (F1174L, L1196M and G1202R) invariably developed. In this work, a series of 2-aminopyridine derivatives were designed and synthesized by C-5 position incorporation of a 2-pyridone moiety and bioisosteric replacement of the C-3 position linkers. Optimization of the 2-aminopyridine derivatives led to the identification of hit 18d displaying a significant growth inhibition against a variety of ALK-addicted cancer cells. Especially in the case of ALK-positive Karpas-299 cell, 18d exhibited excellent anti-proliferative potency with an IC50 value of about 40 nM. Moreover, 18d demonstrated encouraging activities against wild-type ALK (19 nM), ROS1 (2.3 nM) as well as challenging crizotinib-resistant ALKL1196M and ALKG1202R mutants with IC50 values of 45 nM and 22 nM, respectively. Additionally flow cytometric analysis indicates that 18d inhibited Karpas-299 cell viability via G1 phase arrest. Taken together, this work provided a promising ALK inhibitor to circumvent the clinical crizotinib-resistant mutants.

Inhibitors of nedd8-activating enzyme

The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

Aminoheteroaryl compounds and preparation method and use thereof

The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R1 and R3 are defined in the Description in details. The aminoheteroaryl compounds of t